Drug Profile
CRX 526
Alternative Names: CRX-526Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator X-in8
- Developer University of North Carolina at Chapel Hill; X-in8
- Class Anti-inflammatories
- Mechanism of Action Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Reperfusion injury
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Reperfusion-injury in USA (Parenteral)
- 25 Jul 2016 Preclinical development is ongoing for Reperfusion injury